A Chinese bioscience startup, Lonvi Biosciences, has announced the development of a pill it claims could extend human lifespan to as much as 150 years.
The company, based in Shenzhen, said the pill is derived from grape seed extract and targets senescent cells—commonly referred to as “zombie cells”—which are known to contribute to aging and inflammation.
“This is not just another pill. This is the Holy Grail,” Lonvi Chief Executive Officer, Ip Zhu, said in a statement.
According to the firm, the active compound, procyanidin C1 (PCC1), has shown promising results in laboratory mice, increasing their lifespan by 9.4 per cent overall and 64.2 per cent from the start of treatment.
Lonvi’s Chief Technology Officer, Lyu Qinghua, said the company believes living to 150 is “definitely realistic” and expects the pill to become widely available in the coming years.
The announcement comes amid growing interest in longevity science in China, where the average life expectancy reached 79 years in 2024—five years above the global average.
Gan Yu, co-founder of Shanghai-based longevity firm Time Pie, said the trend reflects a shift in public interest. “Nobody in China used to talk about longevity, only rich Americans. Now many Chinese are interested and have the money to extend their lives,” he said.
While Lonvi’s claims have sparked excitement, experts caution that human trials are needed to validate the pill’s effectiveness and safety.
